Results 181 to 190 of about 38,893 (219)

Intranasal Mucosal Atomiser Devices: A Novel Harm Reduction Intervention

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Factors associated with diminished peripheral vein access, including age, prolonged history of injecting drug use and coadministration with other substances, are all increasing among people who inject drugs in Australia. This exposes individuals to increased risk of injecting related complications, including skin and soft tissue ...
Hayden Green, Thileepan Naren, Brittany Chapman, Martyn Lloyd‐Jones, Sione Crawford, Dean Membrey   +5 more
wiley   +1 more source

Examining Differences Among Opioid Agonist Treatment Clients in Regional and Metropolitan Settings of New South Wales, Australia. [PDF]

Aust J Rural Health
Winter DT, Monds LA, Lintzeris N, Haber PS, Day CA.   +4 more
europepmc   +1 more source

Accuracy of Patient‐Reported Exposure to New Psychoactive Substances and Other Illicit Drugs in Australian Emergency Departments: Findings From the Emerging Drugs Network of Australia

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction New psychoactive substances (NPS) present a unique challenge in clinical, public health and drug‐policy contexts. Continued diversity, unknown potency and often unintentional exposure can limit the accuracy of self‐reported data.
Marjan J. Nijmeijer, Jennifer L. Smith, Courtney Weber, Bas W. J. Bens, Daniel M. Fatovich, Shaun L. Greene, Jennifer L. Schumann, Paul Dessauer, Rebekka Syrjanen, Katherine Z. Isoardi, Keith Harris, Sam Alfred, Viet Tran, Ewoud ter Avest   +13 more
wiley   +1 more source

Psychiatrist-led hepatitis C (HCV) treatment at an opioid agonist treatment clinic in Stockholm- a model to enhance the HCV continuum of care. [PDF]

BMC Psychiatry
Klasa PE, Sandell M, Aleman S, Kåberg M.   +3 more
europepmc   +1 more source

Effectiveness of Alcohol Use Disorder Pharmacotherapies by Sex: Systematic Review and Meta‐Analysis

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Issues Alcohol use disorder (AUD) shows sex‐related differences in prevalence, harm and treatment response. Despite growing interest in sex differences, evidence synthesis evaluating pharmacotherapy effectiveness by sex remains limited. Approach Web of Science, PubMed, Scopus, PsycINFO and Cochrane were searched twice.
Juliette Allen, Andrew Jones, Gillian W. Shorter, Catharine Montgomery, Zetta Kougiali, Alina Bagnall, Claire Adshead, Jessie Smith, Sam Burton, Amanda Atkinson, Lillian Guelen, Abigail Rose   +11 more
wiley   +1 more source

Comparative effectiveness of maintenance doses of opioid agonist treatment among individuals with opioid use disorder: a target trial emulation protocol using a population-based observational study. [PDF]

BMJ Open
Zanette M, Min JE, Homayra F, Bach P, Socías ME, Bruneau J, Korthuis PT, Karim E, Seaman S, Bozinoff N, Kennedy MC, Nosyk B.   +11 more
europepmc   +1 more source

Perceptions of Buprenorphine With Naloxone Treatment and the Fear of Precipitated Withdrawal: A Qualitative Exploration With HIV Prevention Trials Network 094 INTEGRA Participants and Staff

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Uptake of evidence‐based medication for opioid use disorder (MOUD), including buprenorphine–naloxone, remains low despite the expanding US opioid crisis. This study examined participants' and staff perceptions of adopting and delivering buprenorphine–naloxone on a mobile unit providing integrated MOUD and HIV services for people ...
Rose A. Schmidt, Amaya Perez‐Brumer, Peter Davidson, Steve Shoptaw, Nabila El‐Bassel, Philip Andrew, Jayla Harris, Omar Nieto, Sydney Bornstein, Rashaunna Redd, Jessica Yeager, David Goodman‐Meza, Albert L. Hasson, Marc Seigel, Cecile Denis, Renee El‐Krab, Laramie R. Smith, on behalf of the HPTN 094 Team   +17 more
wiley   +1 more source

The association between benzodiazepine co-prescription, opioid agonist treatment and mortality: a systematic review. [PDF]

BMC Psychiatry
Hestevik CH, Evensen LH, Kornør H, Skeie I.   +3 more
europepmc   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5767-5778, July 2026.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, Björn Pasternak   +10 more
wiley   +1 more source

Identifying key risk factors for intentional self-harm, including suicide, among a cohort of people prescribed opioid agonist treatment: A predictive modelling study. [PDF]

Addiction
Jones NR, Hickman M, Bharat C, Nielsen S, Larney S, Ghouse NF, Lappin J, Degenhardt L.   +7 more
europepmc   +1 more source